{"name":"Zynerba Pharmaceuticals, Inc.","slug":"zynerba-pharmaceuticals-inc","ticker":"","exchange":"","domain":"zynerba.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ZYN002 - transdermal gel","genericName":"ZYN002 - transdermal gel","slug":"zyn002-transdermal-gel","indication":"Seizure disorders","status":"phase_3"}]}],"pipeline":[{"name":"ZYN002 - transdermal gel","genericName":"ZYN002 - transdermal gel","slug":"zyn002-transdermal-gel","phase":"phase_3","mechanism":"ZYN002, a transdermal gel formulation of cannabidiol, is thought to exert its therapeutic effects through its action on the endocannabinoid system.","indications":["Seizure disorders"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQQXZxRXRoY2hsMWZVQllLQXE3cEg3d2F5TlF5alpJcEpoWW8xaE1Lc3JaLVRfa0FvcEtVTjJsOVpZQTQtWXVPZ3hmTDhoRm9MeS1BdEhkakp4Z2VhRk0yRm9CZll3aWEwSlVnOTFvVlpLa0hoVzJ4TVRSMTZBcllRYWpJbk9CMXAzdU45aGtDY3d6V1dkSXVpMXI3Tl85bWVxNW5nejBWbnVfdVhUbXhXVg?oc=5","date":"2025-09-25","type":"pipeline","source":"seekingalpha.com","summary":"Harmony Biosciences: Cannabinoid Fragile X Fail Merits Rating Downgrade (NASDAQ:HRMY) - seekingalpha.com","headline":"Harmony Biosciences: Cannabinoid Fragile X Fail Merits Rating Downgrade (NASDAQ:HRMY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxPeUx4N1VxLVVxc28zWUFqN2xxa0gwU2xfY2FldkpYcDBDNmFxR2V0azFwVXhGN0dNZFJTd3ZXVzU4cHYtbzZHUmNxVUhKandmdlhuOXM1UHRPbTV6VUs0NEt3WnlSYkZib2JaYTcwM1dOTmlSRzJId0E4bXF1M1FCcmJ6QzFQQ0VtZFVkWGN5aGM0X0FmY1RtQWEzZlNqWWtFQ0pmUHZvNU9SV3Q5LUdiekNaZmo0U2xZNkROM2lMQ05MM1REWkMtLUlYVDg3a29idE4zU3NPekFLRHJUeTZNRzhSSFkzQUhfV0VVbWRTcEtFclpHcUxVYXdXT2JINkhubFBNSzlJSldFMHEyLTliclQwTGpyVlNEWG5XRzdR?oc=5","date":"2025-08-12","type":"trial","source":"globenewswire.com","summary":"Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ - globenewswire.com","headline":"Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9GbTZsWmRiaGQ0RExPR2hmVjRabTFmQ1ZaVG9oWWVLQkNTcWFKRVo2T1pYQ1UwUXJ1ejl0b3RwSWFEaUZkSWd1UkRTdWJyY0JMeURB?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"ZYNE Stock Price, News & Analysis - Stock Titan","headline":"ZYNE Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPaFJ3d1lpSFRJYlFnNXBETHZ2M29ianVMV1hWRnlKUjY5a3pXc0tpVGxGR2hHUkY3bm94clNEZjY2TWFoRjIyZS0tTnEtNllMeEhKanRPSmVVS3pHWHl5akE1T1BQR09LLTdneWtxdHFnUWpzUXVIcDRVaW8yU3BEOTM5ZjVrRWI5TjFmSUNqM25mVzJ4blZmZ0ZfSDVlRnRJdG93dHc0OG9Gbm1iZ1BWSVBkS21oa1dIUXRqMDlMY3ZjV2k5aUtXR3FwVkJCWmY2bkJTaUlnZnFsTWN5VlE?oc=5","date":"2023-10-11","type":"pipeline","source":"PR Newswire","summary":"HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE - PR Newswire","headline":"HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPNFZYeEZBZHFHUVk3ZUVpSS1lT3JDdWowYnFnRVd1bEtjcUVCNXdLdmhhdXBCNHhsZkhXQUlwZmN2Qms2a3h1cDV0Z09tU083Q1Q0UnNCZHhQYnpLRXV3N3JsQ05kTFk3dGQ0bWNFQks2TzJhYzZ0UDYzVm1FZUs4WVZOOUUtZG9FckxVZ1c1M3NST2Z0RGRKQ2dkTXliSlE?oc=5","date":"2023-09-29","type":"pipeline","source":"Yahoo Finance","summary":"Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023 - Yahoo Finance","headline":"Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNTkF2c2ZoMVEyTElCSmU0Q2pwY0laNEs5Q1J2SU00UzZDUHR2ZV84aXdodjhEd2piSlV2SWFvZEh5U3FXLVN4bDJIcmNHODNqdFdhUkdSSEdidDROUWJvTzlTNmFBZXJMNDVRckY4c0ptenlvUjFIaTdSdlg4eV91cUQwQXRSM2cwQTBmZWdZelRYVXpCMEVLZkc0ZEJuZw?oc=5","date":"2023-08-17","type":"deal","source":"Pharmaceutical Executive","summary":"Harmony Biosciences Set to Acquire Zynerba Pharmaceuticals for $60M - Pharmaceutical Executive","headline":"Harmony Biosciences Set to Acquire Zynerba Pharmaceuticals for $60M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNaEZJTVpPdUVNX0pNTFB6QjNtbmNUbXNaa21sbWlkekJVaXdvYnFyVDBhQkF6VmNBQjdzY3RWTWVJQjZORWx0SE5TQVF2Yy1ObmtEUzhxN0pTTU00WmpXNHpHRjl6ZnVhZXNJaEl1V1RTNmp4cmpibm02S1lPYl9ZSHBPbmN4am52QXJ2SDBJN000ckVmYi1iWGdoQWVpR1RiSlZDQlhuVHF2Wm5DYXM1ak9jcDgtS04zN1lLcnM5cWdjU0RJZG1xLW5n?oc=5","date":"2023-08-14","type":"deal","source":"Proactive financial news","summary":"Zynerba Pharma stock rockets on premium priced Harmony deal - Proactive financial news","headline":"Zynerba Pharma stock rockets on premium priced Harmony deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPRzRRMDQ3WFAtaFZIWmFRbU9ZTHo5SE1SZGl4TzJ2RkMyWU05MUNKSHNjQzFNeDhkeE1McXlDLUFfS1E2RE5LMU8zZXlZajNWN0s0ci1tY01LRUtYckpEUEJEN1hIYW1FaTQtcnRLZDBOVWFCTVVwNFpfTDB2TzZEbWtycGZqbEp4NGQyZ1dMTXg0Wkx5dVRrU0ZyTG5DaUp4TzJFWkozcWlMWHRJSlRQME8yYlc?oc=5","date":"2023-08-14","type":"deal","source":"PR Newswire","summary":"HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. - PR Newswire","headline":"HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQR29oUUVHajgxUlhXMmFRd29Id3NxVHBNS19QOXlMV1lXaFBjN1pBMjZFYl9qWGk0VTJFckd1NXpYRmlzaVVDUEQ0aVBYX3FKb05MbmozcHBVWW5KSEZMbnk5ZUVFSFliY1dhZ2htUDlDMVZzSThVeGNRRVB3RDFyVzRpR0pCamVBbzdmcG1XcE9QWkFOam9kWVdn?oc=5","date":"2023-08-14","type":"deal","source":"MedCity News","summary":"Harmony Bio’s Zynerba Buyout Brings Cannabinoid That Doesn’t Spark Euphoria - MedCity News","headline":"Harmony Bio’s Zynerba Buyout Brings Cannabinoid That Doesn’t Spark Euphoria","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2019-01-04","type":"pipeline","source":"simplywall.st","summary":"Do Directors Own Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Shares? - simplywall.st","headline":"Do Directors Own Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Shares?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNUko1d3dKX3NwOHM2M3h2Y2JDU1RXbUtHX2sxdF9tZWotMlV3Ulk4YjA4VmNod3VRNHM5bnZHMDA3OFh1U0lRdmNieUpiSHNuTXVOVjFQeHRRcDl0NUNmcFJra1RyemM3cnc2UGNRTlBtM3hHdkR0cWwwbnpXNlpaMTNHRnVsTTZEZmxhdi1ha0RnTU5x?oc=5","date":"2018-07-05","type":"pipeline","source":"BioPharma Dive","summary":"After failure, Zynerba shifts gears to save cash - BioPharma Dive","headline":"After failure, Zynerba shifts gears to save cash","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNR1BaNlJCb0pNWmMxSHEyeG5XaUJvZWNISnY5dGk0Zjl1ZW1TVHlDRnVFNTExU29hTGthbWhYcnNqX3Bnd2JZaTgtZFp5YndvZEZmN0hpdG51aW83ZTVUeXhwbl9meXRGUTQxOUZ2MmpSYVFTQ1ZuSGVCYlFSdjdvWU05eHcwaE9IdEY0TzZB0gGOAUFVX3lxTE1HUFo2UkJvSk1aYzFIcTJ4bldpQm9lY0hKdjl0aTRmOXVlbVNUeUNGdUU1MTFTb2FMa2FtaFhyc2pfcGd3YllpOC1kWnlid29kRmY3SGl0bnVpbzdlNVR5eHBuX2Z5dEZRNDE5RnYyalJhUVNDVm5IZUJiUVJ2N29ZTTl4dzBoT0h0RjRPNkE?oc=5","date":"2016-10-18","type":"pipeline","source":"marketexclusive.com","summary":"Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Files An 8-K - marketexclusive.com","headline":"Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Files An 8-K","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}